2023 Top Story in Dermatology: Efficacy and Managing Long-Term Use of Dupilumab
This past year was another promising and hopeful year for pediatric patients with atopic dermatitis (AD). Dupilumab continues to be the most frequently prescribed systemic agent for patients with moderate to severe disease,1 and providers have become very comfortable prescribing dupilumab to pediatric patients, even infants.2,3 This has been a game-changing addition to our therapeutic ladder, and two publications supported decreasing the frequency of injections while maintaining efficacy for those patients with well-controlled disease.4 This evidence is important and supportive for providers managing dupilumab administration long-term. Moreover, upadacitinib and abrocitinib are both approved in pediatric patients 12 years and older,2 expanding our treatment toolbox for those needing a different systemic agent. Further approval is likely on the horizon for pediatric AD. The efficacy and safety results from the BREEZE-AD baricitinib pediatric trial were published in April.2
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
- Valente C, Farinha P, Duarte B. Extending dupilumab dosing intervals in atopic dermatitis: a prospective observational study in a South European tertiary hospital. J Eur Acad Dermatol Venereol. 2023 Sep 20. doi: 10.1111/jdv.19528. Online ahead of print.
- Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189(1):23-32.
- Paller AS, Ladizinski B, Mendes-Bastos P, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the Measure Up 1, Measure Up 2, and AD Up randomized clinical trials. JAMA Dermatol. 2023;159(5):526-535.
- Ardern-Jones MR, Buchanan EE, Njungu S, et al. Successful dose reduction of dupilumab in atopic dermatitis. Br J Dermatol. 2023;188(5):678-679.
Disclosure statements are available on the authors' profiles: